Mizuho Securities Keeps Their Buy Rating on Evolus Inc

In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Evolus Inc (NASDAQ: EOLS), with a price target of $21. The company’s shares opened today at $9.43.

According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.0% and a 47.0% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Adamas Pharmaceuticals, and Eagle Pharmaceuticals.

Currently, the analyst consensus on Evolus Inc is Moderate Buy and the average price target is $23, representing a 143.9% upside.

In a report issued on April 25, Cantor Fitzgerald also maintained a Buy rating on the stock with a $25 price target.

Find more picks by Best Performing Analysts >>

Based on Evolus Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $4.45 million. In comparison, last year the company had a GAAP net loss of $3.74 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolus, Inc. is a medical aesthetics company. The company is engaged in providing physicians and patients with expanded choices in aesthetic procedures and treatments. Evolus was founded in November, 2012 and is headquartered in Irvine, CA.